X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) – Investment analysts at B. Riley upped their Q2 2023 earnings per share estimates for shares of X4 Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 17th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings of ($0.19) per share for the quarter, up from their prior forecast of ($0.22). B. Riley currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.65) per share. B. Riley also issued estimates for X4 Pharmaceuticals’ Q3 2023 earnings at ($0.20) EPS, Q4 2023 earnings at ($0.18) EPS, FY2023 earnings at ($0.74) EPS and FY2024 earnings at ($0.34) EPS.
XFOR has been the subject of a number of other research reports. Oppenheimer cut their price target on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set an “outperform” rating for the company in a research note on Friday, March 24th. Stifel Nicolaus raised their price target on X4 Pharmaceuticals from $4.00 to $5.00 in a research report on Wednesday, May 17th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $3.00 price objective on shares of X4 Pharmaceuticals in a report on Wednesday, March 22nd. Finally, HC Wainwright decreased their price objective on X4 Pharmaceuticals from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Wednesday, March 22nd. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $3.50.
X4 Pharmaceuticals Price Performance
X4 Pharmaceuticals (NASDAQ:XFOR – Get Rating) last posted its earnings results on Tuesday, March 21st. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06).
Hedge Funds Weigh In On X4 Pharmaceuticals
Several institutional investors and hedge funds have recently bought and sold shares of XFOR. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of X4 Pharmaceuticals during the third quarter valued at approximately $39,000. Virtu Financial LLC bought a new stake in X4 Pharmaceuticals in the 1st quarter worth $45,000. Jane Street Group LLC purchased a new position in shares of X4 Pharmaceuticals in the first quarter valued at about $64,000. CIBC Private Wealth Group LLC bought a new position in shares of X4 Pharmaceuticals during the first quarter valued at about $36,000. Finally, Landscape Capital Management L.L.C. purchased a new stake in shares of X4 Pharmaceuticals during the first quarter worth about $37,000. 56.46% of the stock is currently owned by institutional investors.
X4 Pharmaceuticals Company Profile
X4 Pharmaceuticals, Inc operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003.
- Get a free copy of the StockNews.com research report on X4 Pharmaceuticals (XFOR)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.